--News Direct--
Todos Medical president and CEO Gerald Commissiong joins Proactive's Natalie Stoberman to discuss news of the company entering a Letter of Intent with Provista Diagnostics to license PCR-based sepsis diagnostic test AcuSept LDT rights From Acumen Diagnostics.
Todos Medical engineers life-saving diagnostic solutions for the early detection of a variety of cancers. The company's state-of-the-art and patented Todos Biochemical Infrared Analyses (TBIA) is a proprietary cancer-screening technology using peripheral blood analysis that examines cancer's influence on the immune system, looking for biochemical changes in blood mononuclear cells and plasma.
Contact Details
Proactive Investors
+1 347-449-0879
na-editorial@proactiveinvestors.com
View source version on newsdirect.com: https://newsdirect.com/news/todos-medicals-letter-of-intent-with-provista-diagnostics-set-to-license-sepsis-diagnostic-testing-214995662
